Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 65 or older who are unable to tolerate chemotherapy, of any gender
• People with a general health and activity level rated as ECOG 0–1 (meaning largely able to carry out daily activities), and a disease risk score (IPI) of 3 or below
• People whose life expectancy is estimated to be more than 3 months
• People diagnosed with a specific type of lymphoma called DLBCL (Diffuse Large B-Cell Lymphoma), confirmed by a tissue biopsy
• People whose blood test results — taken within the last 7 days — show adequate levels of infection-fighting cells, platelets, and red blood cells, with no reasons that would make chemotherapy unsafe (confirm with trial site)
• People who have at least one tumour that can be measured on a scan, meeting specific size requirements depending on whether it is in a lymph node or another part of the body (confirm with trial site)
• People whose liver function test results are within acceptable ranges as defined by the trial (confirm with trial site)
• People whose kidney function test results are within acceptable ranges as defined by the trial (confirm with trial site)
• People without other serious illnesses that would conflict with the trial treatment
• People with normal heart function, aside from any other conditions already noted
• People who are not currently receiving other anti-tumour treatments, including traditional Chinese medicines with anti-tumour effects, immunotherapy, or biological therapies (treatment for bone symptoms may be acceptable — confirm with trial site)
• People who are willing to take part voluntarily, sign a consent form, and attend follow-up appointments
• People who, during the treatment period, are not using other anti-tumour drugs at the same time (bone-related treatments such as bisphosphonates and other symptom-relief treatments may be permitted — confirm with trial site)

Who may not be able to join:

• People with a diagnosed neurological or psychiatric condition, including dementia or epilepsy, a history of psychotropic drug misuse that has not been resolved, or other brain-related conditions that could increase the risk of nervous system side effects
• People currently taking part in another clinical trial, or who took part in one within the 4 weeks before joining this trial (unless no treatment was actually received in that trial)
• People with a systemic autoimmune disease or a condition that weakens the immune system
• People who are unwilling to have blood samples collected
• People with a known allergy to any medication included in the trial treatment plan
• Women who are pregnant or breastfeeding
• People with major diseases or uncontrolled active infections that could interfere with the trial
• People with tumours that started in or have spread to the brain or central nervous system
• People for whom chemotherapy is medically unsuitable
• People who have received Rituximab, Ibrutinib (Obutinib), Compound Cyclophosphamide Tablets, or Azacitidine within the past 28 days
• People whom the trial researchers consider unsuitable for inclusion, for any reason
• People with a known active infection (bacterial, viral, fungal, or other), or who required intravenous antibiotics or hospitalisation for an infection in the 4 weeks before joining (excluding fever caused by the tumour itself; minor nail or skin fungal infections are not excluded)
• People currently receiving other anti-tumour treatments such as radiotherapy, chemotherapy, hormone therapy, biological therapy, or immunotherapy
• People with any of the following serious conditions: uncontrolled diabetes; severe heart failure (NYHA Grade II or above); a heart attack or acute coronary event in the past 6 months; heart or major blood vessel surgery (including stent placement or bypass surgery) in the past 6 months; serious heart rhythm problems including frequent irregular heartbeats, fast or unstable heart rhythms, or very slow heart rate; uncontrolled high blood pressure (systolic above 150 mmHg or diastolic above 100 mmHg); stomach ulcers considered at risk of perforation; active autoimmune diseases (such as lupus, rheumatoid arthritis, multiple sclerosis, or similar conditions); or severe lung or breathing conditions
• People with a condition called haemophagocytic syndrome (a serious immune system disorder)
• People who test positive for Hepatitis B surface antigen or Hepatitis B core antibody with abnormal Hepatitis B virus levels in the blood; people with both a positive Hepatitis C antibody and detectable Hepatitis C virus in the blood; people who test positive for HIV; people who test positive for Cytomegalovirus (CMV) DNA; or people who test positive for syphilis

Important: Always verify eligibility with the trial site directly before applying.